BIO Asia–Taiwan 2024, an international gathering jointly organized by the global Biotechnology Innovation Organization (BIO) and the Taiwan Bio Industry Organization (Taiwan BIO); will be held from July 24th to 28th at the Taipei Nangang Exhibition Center. Amaran Biotech’s booth(#M413) will be located at CDMO (Contract Development and Manufacturing Organization) zone, please visit us and meet with our representatives.
It is well known that human intervention increases the risk of finished product sterility failure during the aseptic filling process. For traditional aseptic filling lines using RABS, human intervention is often required, such as adjusting conveyor belts, turntables, vibrating bowls, star wheels through gloves.
When it comes to the production of sterile products, EU GMP Annex 1 is the highest standard that pharmaceutical manufacturers must adhere to. To provide a Class A environment and ensure sterility, barrier technology (either isolators or RABS) is the best solution to address critical factors such as quality of air, material and ingredient transfer, decontamination, etc. mentioned in Annex 1.
BIO Asia–Taiwan 2023, an international gathering jointly organized by the global Biotechnology Innovation Organization (BIO) and the Taiwan Bio Industry Organization (Taiwan BIO); will be held from July 27th to 30th at the Taipei Nangang Exhibition Center, Hall 1 (TaiNEX 1).
The world's largest biotechnology industry event "BIO International Convention 2023" will be held at the Boston Convention & Exhibition Center on June 5-8. Amaran Biotech, is invited by the Biotechnology and Pharmaceutical Industries Promotion Office, Ministry of Economic Affairs (BPIPO, MOEA) and the Taiwan External Trade Development Council (TAITRA), will jointly exhibit at the "Taiwan Pavilion".
Amaran Biotechnology Inc., a subsidiary of Taiwan’s OBI Pharma Inc., today announced that the construction of its fully-automated aseptic filling line and facilities, a first in Taiwan, has been completed. The new facility minimizes the risks of human factors affecting the quality of the pharmaceutical products, and substantially enhances their safety. The project is now entering the final process validation phase of the medium fill procedures.